| Active substance | nivolumab and ipilimumab |
| Holder | Bristol-Myers Squibb SA/NV |
| Status | closed |
| Indication | First line treatment of adult patients with unresectable malignant pleural mesothelioma |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 11/08/2022 |